PDCD1 and non-small cell lung carcinoma: Anti-programmed death 1 (PD-1) and anti- programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs) have profoundly produced durable anticancer responses in patients with a variety of solid tumors, including NSCLC.